Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
Myeloid Therapeutics
Novartis
MacroGenics
Nurix Therapeutics, Inc.
Xencor, Inc.
858 Therapeutics, Inc.
Toray Industries, Inc
Telix Pharmaceuticals (Innovations) Pty Limited
Medicenna Therapeutics, Inc.
Instituto do Cancer do Estado de São Paulo
Klus Pharma Inc.
Theratechnologies
Stanford University
Cybrexa Therapeutics
Carisma Therapeutics Inc
Salubris Biotherapeutics Inc
Hoffmann-La Roche
Eli Lilly and Company
Instil Bio
Canadian Cancer Trials Group
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Eastern Cooperative Oncology Group
Xencor, Inc.
MacroGenics
Gilead Sciences
Novartis
Jonsson Comprehensive Cancer Center
Abramson Cancer Center at Penn Medicine
City of Hope Medical Center
City of Hope Medical Center
Pfizer
Wake Forest University Health Sciences
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
University of Louisville
Fred Hutchinson Cancer Center
Rutgers, The State University of New Jersey
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
University of Southern California
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Barbara Ann Karmanos Cancer Institute
University of Arizona
City of Hope Medical Center
Valerio Therapeutics
National Cancer Institute (NCI)